Oak Hill Bio to merge with RA Capital SPAC as InnoCare’s TYK2 candidate reports positive Phase 3 results

Oak Hill Bio, a biotech focused on Angelman syndrome, announced it will combine with RA Capital’s special purpose acquisition company, Research Alliance Corporation III. The transaction will give Oak Hill Bio access to public‑market capital and resources to advance its pipeline.

The merger is part of a broader wave of SPAC activity in the biotech sector, allowing companies to accelerate development timelines and broaden investor reach.

In parallel, InnoCare reported that its TYK2 inhibitor achieved its primary endpoints in a Phase 3 trial, signaling a potential new therapy for its target indication. The positive readout adds momentum to the sector’s pipeline advancements.